Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.
Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Such vaccines could help protect against influenza and other respiratory viruses, or prevent sexually transmitted diseases such as HIV, herpes simplex virus and human papilloma virus, says Darrell Irvine, an MIT professor of materials science and engineering and biological engineering and the leader of the research team. He is also exploring use of the particles to deliver cancer vaccines.
“This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.
Irvine and colleagues describe the nanoparticle vaccine in the Sept. 25 issue of Science Translational Medicine. Lead authors of the paper are recent PhD recipient Adrienne Li and former MIT postdoc James Moon.
Only a handful of mucosal vaccines have been approved for human use; the best-known example is the Sabin polio vaccine, which is given orally and absorbed in the digestive tract. There is also a flu vaccine delivered by nasal spray, and mucosal vaccines against cholera, rotavirus and typhoid fever.
To create better ways of delivering such vaccines, Irvine and his colleagues built upon a nanoparticle they developed two years ago. The protein fragments that make up the vaccine are encased in a sphere made of several layers of lipids that are chemically “stapled” to one another, making the particles more durable inside the body.
“It’s like going from a soap bubble to a rubber tire. You have something that’s chemically much more resistant to disassembly,” Irvine says.
This allows the particles to resist disintegration once they reach the lungs. With this sturdier packaging, the protein vaccine remains in the lungs long enough for immune cells lining the surface of the lungs to grab them and deliver them to T cells. Activating T cells is a critical step for the immune system to form a memory of the vaccine particles so it will be primed to respond again during an infection.
Stopping the spread of infection
In studies of mice, the researchers found that HIV or cancer antigens encapsulated in nanoparticles were taken up by immune cells much more successfully than vaccine delivered to the lungs or under the skin without being trapped in nanoparticles.
HIV does not infect mice, so to test the immune response generated by the vaccines, the researchers infected the mice with a version of the vaccinia virus that was engineered to produce the HIV protein delivered by the vaccine.
Mice vaccinated with nanoparticles were able to quickly contain the virus and prevent it from escaping the lungs. Vaccinia virus usually spreads to the ovaries soon after infection, but the researchers found that the vaccinia virus in the ovaries of mice vaccinated with nanoparticles was undetectable, while substantial viral concentrations were found in mice that received other forms of the vaccine.
Mice that received the nanoparticle vaccine lost a small amount of weight after infection but then fully recovered, whereas the viral challenge was 100 percent lethal to mice who received the non-nanoparticle vaccine.
“Giving the vaccine at the mucosal surface in the nanocapsule form allowed us to completely block that systemic infection,” Irvine says.
The Latest on: Nanoparticle vaccine
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
on March 14, 2018 at 1:17 pm
About NanoFlu™ and Matrix M™ NanoFlu vaccine is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu vaccine uses HA amino acid protein sequences that ... […]
Global Nanoparticle Tracking Analyzer Market 2017 Malvern Instruments, Agilent Technologies
on March 9, 2018 at 8:17 pm
Nanoparticle Tracking Analyzer market studies the competitive ... supported Application Coverage , Nanoparticle Toxicology , Drug Delivery , Exosomes , Vaccine Production , Other , , The Nanoparticle Tracking Analyzer report will the thorough study ... […]
N4 Pharma Nuvec® Update
on March 8, 2018 at 3:30 am
Nuvec® is a nanosilica system which targets the delivery of therapeutics such as RNA, DNA, vaccines and targeted cancer therapies and is being positioned as a potential alternative delivery system to lipid nanoparticles and lipid nanosomes. The Company is ... […]
N4 Pharma reveals development strategy for Nuvec program
on March 7, 2018 at 10:53 pm
Nuvec is a nanosilica system which targets the delivery of therapeutics such as RNA, DNA, vaccines and targeted cancer therapies and is being positioned as a potential alternative delivery system to lipid nanoparticles and lipid nanosomes. APPOINTMENT OF ... […]
Nanoparticle vaccine for universal protection against influenza
on February 1, 2018 at 12:45 am
Atlanta - Scientists have developed a novel universal vaccine to combat influenza A viruses. The new vaccine aims to produce long-lasting immunity. The results to date are based on studies undertaken using an animal model. For the research, as reported in ... […]
New nanoparticle-based vaccine to combat influenza A viruses
on January 24, 2018 at 6:42 am
A new vaccine developed using nanoparticles offers universal protection against several influenza A viruses such as H1N1, H3N2, H5N1 and H7N9, researchers say. Influenza, a contagious respiratory illness that infects the nose, throat and lungs, is among ... […]
New nanoparticle-based vaccine to combat influenza A viruses
on January 24, 2018 at 6:07 am
New York, Jan 24 (IANS) A new vaccine developed using nanoparticles offers universal protection against several influenza A viruses such as H1N1, H3N2, H5N1 and H7N9, researchers say. Influenza, a contagious respiratory illness that infects the nose ... […]
Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine
on August 23, 2017 at 4:03 am
Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax ... […]
via Google News and Bing News